adjuvanted inactivated vaccine against porcine circovirus type 2

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Circovac. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Circovac.

For practical information about using Circovac, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 08/12/2021

Authorisation details

Product details
Agency product number
Active substance
inactivated porcine circovirus type 2 (PCV2)
International non-proprietary name (INN) or common name
adjuvanted inactivated vaccine against porcine circovirus type 2
Pigs (gilts and sows)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
CEVA-Phylaxia Oltóanyagtermelõ Zrt.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Szállás u. 5.
1107 Budapest

Product information

09/09/2021 Circovac - EMEA/V/C/000114 - WS1945/0018

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

Sows and gilts

Passive immunisation of piglets via the colostrum, after active immunisation of sows and gilts, to reduce lesions in lymphoid tissues associated with PCV2 infection and as an aid to reduce PCV2-linked mortality.


Active immunisation of piglets to reduce faecal excretion of PCV2 and virus load in blood, and as an aid to reduce PCV2-linked clinical signs, including wasting, weight loss and mortality, as well as to reduce virus load and lesions in lymphoid tissues associated with PCV2 infection.

Assessment history


How useful was this page?

Add your rating